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Abstract 
Thyroid gland diseases are among the most common endocrine diseases and still continue to be an important health 
problem especially in developing countries. It was aimed to investigate serum NO, ADMA and Apelin levels in 
patients with thyroid dysfunction. This study was conducted with 150 thyroid patients and 50 healthy subjects. 
Study subjects were divided into three groups; control (n=50), hyperthyroid ( n=75) and hypothyroid (n=75). 
Serum TSH, FT3, FT4   levels  were  measured  by  chemiluminescence  method  NO  level  were  measured  by 
spectrophotometric method, ADMA and apelin levels were measured by ELISA. Serum NO levels were higher in 
hypothyroid group than in hyperthyroid group, and the difference was statistically significant. Serum ADMA 
levels of the hyperthyroid group were significantly higher than the other two groups and the difference was 
statistically significant. The levels  of  serum  apelin  were  statistically significantly higher in the hyperthyroid 
group than the other two groups. In patients with hyperthyroidism, ADMA and Apelin levels were higher, while 
NO level was lower. However, NO level was higher in patients with hypothyroidims than the other two groups. 
Apelin, which has been emphasized  as  a  preventive  and  therapeutic  agent  particularly  for  the cardiovascular 
system, might have increased in hyperthyroid patients, regardless of NO, to protect cardiovascular system from 
possible adverse effects of ADMA. 
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1. Introduction 
Thyroid gland diseases are among the most common endocrine diseases and still continue to be an important health 
problem especially in developing countries (Arıkan et al.2007; Demers and Spercer 2003). Thyroid diseases may 
be  classified  as  hyperthyroidism,  hypothyroidism,  subclinical  hyperthyroidism  and subclinical hypothyroidism, 
according to the level of thyroid hormones. Thyroid diseases may lead to endothelial dysfunction; however, the 
mechanism underlying the endothelial dysfunction in thyroid disease is not clear yet (Gürel et al. 2015; Obregon 
2014). In addition, in case of hypothyroidism during which thyroid hormones are less secreted and in case of 
hyperthyroidism during which thyroid hormones are excessively secreted, the effects of these hormones on lipid 
metabolism and cholesterol levels continue to be the subject of various studies (Stephan et al. 2001; Ana et al. 
2001). 
In recent years, the thyroid dysfunction which is not sufficiently treated has been reported to be among the 
most common underlying causes of cardiovascular diseases. Besides, it has been stated that the timely 
identification of cardiac symptoms and effective treatment are required  in patients  with thyroid  dysfunction 
(Gerdes et al. 2010; Galli et al. 2010; Biondi et al. 2010).  It has  been reported that  the early diagnosis of the 
pathological findings of cardiovascular diseases  in patients with thyroid dysfunction  can  make  significant  
contributions  in  the  prevention  of  the  development, prognosis and treatment of endothelial dysfunction and 
heart failure (Siu et al. 2007; Bernadette 2012). The endothelial which  is  the  main  regulator  of  vascular  
homeostasis  provides  the  balance  between vasoconstriction and vasodilatation, smooth muscle cell proliferation 
and the inhibition and stimulation of migration, thrombogenesis, and fibrinolysis. However, endothelial 
dysfunction occurs if this balance is disrupted. The disruption of the endothelial function is the earliest symptom 
which is the sign of coronary artery disease (Kinlay et al.2001). 
The nitric oxide (NO) which is the major vasodilator secreted from endothelium is synthesized from 
endogenic L-arginine by the nitric oxide synthase (NOS) enzyme system in many tissues in the body. NO is the 
regulatory molecule that functions both intracellularly and extracellularly (Albecht et al.2003).   NO, one of the 
molecules playing the main role in the regulation of vascular tone, may be affected by these function changes in 
the cardiovascular system and play a role in the pathophysiology of these changes (Quesada et al. 2002). The 
activity of NOS enzyme, which is responsible for the synthesis of NO, is regulated by the asymmetric 
dimethylarginine (ADMA) molecule which is an endogenous inhibitor. The fact that ADMA is the major inhibitor 
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of NO biosynthesis has been demonstrated in many studies (Khazan et al. 2015; Chan et al.2002). It is considered 
that the ADMA increase that causes imbalances in the path of NO synthase has a significant role in atherogenesis 
by causing endothelial dysfunction (Böger 2003). 
Apelin, the physiological effects of which are largely unknown, which is alleged to be associated with the 
cardiovascular system and NO, has been defined as a vasoactive peptide which is an endogenous ligand of the 
angiotensin-like receptor (APJ) (Ines et al. 2005; Szokodi et al. 2002). Some cardiovascular functions of 
Apelin/APJ system have been identified such as endothelium- related vasodilation, direct effect on the smooth 
muscle and vasoconstriction. In addition, apelin has been suggested to cause endothelium-related vasodilation by 
means of NO. Apelin has been reported to loosen the vascular and muscular structure by supporting the 
phosphorylation and activation of endothelial nitric oxide synthase (eNOS) that increases NO secretion (Tatemoto 
et al. 2001; Kleinz and Davenport 2005). It is not yet clear if there is a relationship between the blood levels of 
apelin and thyroid hormones, and if thyroid hormones have an effect on apelin levels, although both apelin and 
thyroid hormones play important roles in metabolism. From this point of view, it is worth investigating if apelin 
levels change in thyroid disorders (Gürel et al.2015). 
The aim of our study is to provide an insight on the etiopathogenesis of the relationship between thyroid 
dysfunction and cardiovascular diseases which has not been fully clarified yet by investigating the serum NO, 
ADMA and apelin levels in thyroid dysfunction posing a significant risk for cardiovascular diseases. 
 
2. Material and Methods 
2.1. Study Group and Patient Selection 
This prospective study was carried out on the patients with hyperthyroidism and hypothyroidism aged between 18 
- 60 who had not received a treatment for the thyroid disease in the past three months and applied to internal 
diseases, surgery and goiter polyclinic in Rize Fındıklı Goitre Research Center and Artvin State Hospital between 
April-December 2012. Those who had used antihyperlipidemic drug in the past three months, those with impaired 
glucose tolerance and impaired fasting tolerance reflecting the known diabetes or insulin resistance, those who 
used drugs affecting the insulin and glucose metabolism (steroids, metformin, etc.) and those who used heart and 
blood pressure drugs were not included in the study. 
In addition, those who were followed due to renal dysfunction and malignancy, those with known liver disease 
and those with immunological and chronic infectious diseases were also not included in the study. The people in 
the control group which was formed for the comparison were selected from healthy people who also applied to the 
same polyclinics for general control, did not have the apparent disease and did not use drugs regularly for any 
reason. A total of 200 people including 150 thyroid patients, 75 of them were diagnosed with hyperthyroidism 
( graves, subclinics hyperthyroidism, toxic nodular goiter) and 75 of them were diagnosed with hypothyroidism 
(Hashimato thyroid simple diffuse goiter, subclinical hypothyroidism) and 50 healthy individuals were included 
in the scope of the study. Individuals who were included in the study were divided into three groups as the control 
group (n=50), hyperthyroidism group (n=75) and hypothyroidism group (n=75). The study protocol was presented 
to "Atatürk University Faculty of Medicine, Non-Drug Clinical Research Ethics Committee", and approval was 
received with the protocol dated 27.04.2012 and numbered B.30.2.ATA./1. The "informed consent forms" were 
signed by all of the individuals who were included in the study by providing detailed information about the study. 
The study was planned and implemented in compliance with the Helsinki Declaration. 
 
2.2. Blood sample collection and Demographic Data 
In this prospective study, demographic data of patients such as age, gender and BMI were collected by face-to-
face interview. In this prospective study, demographic data of the patients such as age, gender and BMI were 
collected by face-to-face interview. The data obtained were recorded in the study information form. Blood sample 
collection overnight fasting morning blood samples were obtained from each participants and collected from an 
antecubital vein.  After centrifugation at 4000 x g for 10 minute, Thyroid-Stimulating hormone (TSH), free-
triiodothyronine (FT3), free-tetraiodothyronine (FT4) and biochemistry parameters were studied.  were studied in 
serum. For measurements of apelin, NO and ADMA, serum samples were stored at -80ºC until analysis.  
 
2.3. Biochemical Analyses 
Plasma TSH, FT3  and FT4  levels were determined by chemiluminescence using COBAS E-601 (Model E-
Extensiyon, Serial No:0848-5, Japan) analyzer with Roche Diagnostik kits. Quantitative parameters of serum 
ADMA and apelin levels were measured by Enzyme Linked Immunosorbent Assay (ELISA) using (Bio-tek Power 
Wave –Xs Elısa, USA)  ELISA test kits. The apelin results were stated as ng/ml. The ADMA results were stated 
as µmol/l. Serum NO level was measured by spectrofotometric method using of microplate reader with 
OxisResearch (Catalog No: 22110, Lot No:16527, INC) test kit. The NO results were stated as µM. 
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2.4. Statistical Analysis 
Statistical analyses were performed using the SPSS 17.0. All variables were checked for normal distribution with 
Shapiro–Wilk test. One-way ANOVA with post-hoc Tukey test was applied for multiple comparison of normally 
distributed data. The values are presented as mean ± SD. Differences were considered significant at p < 0.05. 
 
3. Result 
There was a significant difference between the groups participating in the study in terms of average age. While the 
mean age of the control group was lowest, the average age of the hyperthyroid group was highest. These data are 
given in table 3.1. 
The biochemical characteristics of the groups are summarized in Table 3.2. There were no significant 
difference in glucose, TG and fT3 levels between all the groups (p>0.05). Both TC and LDL-C levels were 
significantly higher in hyperthyroid and hypothyroid groups compared to control group (p<0.01), and also serum 
HDL-C concentrations were significantly lower than thyroid diseases groups (p<0.05). In hyperthyroid group, 
TSH levels were significantly lower compared to control (p<0.05) and hypothyroid groups (p<0.01). Patients with 
hypothyroid had higher TSH levels than to control and hyperthyroid groups (p<0.05). fT4 levels in subjects with 
hyperthyroid group were elevated compared to control and hypothyroid groups (p<0.01). There was no significant 
difference in serum fT4 levels between control and hypothyroid groups (p>0.05). 
Serum NO levels were higher in hypothyroid group compared to control and hyperthyroid groups (p<0.05) 
(Fig 1). There was no significant difference in serum NO levels between control and hyperthyroid groups (p>0.05). 
Highest value of ADMA (Fig 2) and apelin (Fig 3) levels were observed in hyperthyroid group and statistically 
significant compared to control and hypothyroid groups (p < 0.01). There was no significant difference in serum 
apelin and ADMA levels between control and hypothyroid groups (p>0.05). 
Table 3.1. Clinical and physical properties of control group, hyperthyroid group and hypothyroid group. 









Age (Years) 34.76 ± 12.66 b 43.92 ± 9.06 c 39.48 ± 9.76a p<0.05 
Women (n),% 
Male (n),% 
(n= 29), % 58  
(n= 21), % 42 
(n= 69), % 92 
(n= 6), % 8 
(n= 74), % 99 
(n= 1), % 1 
 
BMİ (kg/m2) 24.99 ± 4.67b 28.53 ± 4.95a 28.54 ± 5.67 a p < 0.05 
* Data are shown as mean ± mean standard deviation (OSS). Different superscripts in the same line show 
differences between groups (p <0.05). 
 















TC (mg/dl)                 155.34 ± 55.77a 195.92 ± 55.25c  195.37 ± 49,37c p<0.01 
Glucose (mg/dl)  90.62 ± 45.13a 94.59 ± 20.27a 90.07 ± 16.66a p>0.05 
HDL-C (mg/dl)          35.50 ± 9.56a 43.01 ± 10.52b 42.61 ± 13.07b p< 0.05 
LDL-C (mg/dl)       85.38 ± 43.44a 122.50 ± 40.86c 118.37 ± 42.07c p<0.01 
TSH (µlU/ml )      1.72 ± 1.04a 1.15 ± 2.02a 2.71± 3.25b p<0.05 
FT3   ( pg/ml)          2.99 ± 0.46a 2.99 ± 0.56a 2.85± 0.50a p>0.05 
FT4   (ng/dl)          1.27 ± 0.34a 3.68 ± 2.27c 1.20±0.28a p<0.01 
  Abbreviations: HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol;  
  TC, total cholesterol; TG, triglyceride, TSH, Thyroid-Stimulating Hormone; FT3, free-triiodothyronine; FT4, 
free-tetraiodothyronine 
  *All values are mean±SD.a,b,c Means in the same row with different superscripts differ significantly (p>0.05, p 
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           Figure 1. NO levels of the groups. 
           * Means in the same row with different superscripts differ significantly p < 0.05 
 
        Figure 2. ADMA levels of the groups. 
       * Means in the same row with different superscripts differ significantly p < 0.01 
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    Figure 3. Apelin levels of the groups. 
   * Means in the same row with different superscripts differ significantly p < 0.01 
 
Discussion 
Thyroid dysfunction has been an important health problem for many years all over the world without decreasing 
its prevalence. Thyroid dysfunction is an important picture which has negative effects on the quality of life and 
life expectancy of individuals along with its all signs and symptoms and threatens many systems by progressing 
when its diagnosis and treatment are delayed. It has been determined by many studies that the cardiovascular 
system is one of the most important systems affected by thyroid dysfunction. The early diagnosis and treatment of 
cardiovascular diseases, one of the important symptoms and complications in thyroid dysfunction, are particularly 
important. 
The changes in the thyroid hormone levels in both directions may affect metabolic, physiological and 
biochemical processes, and almost all systems of the body (Gürel et al.2015). Many studies have been carried out 
on the effects of thyroid dysfunction on the cardiovascular system. However, the mechanisms of the negative 
effects formed in thyroid dysfunction could not have been illuminated completely (Dillman 2010; Klein and 
Ojamaa 2001). Therefore, the amounts of many substances with the effects on the cardiovascular system in thyroid 
dysfunction have been discussed in some studies (Arikan et a. l 2007; Hemenegildo et al.2002). The regular and 
sufficient synthesis of NO, one of these substances, is important for many systems in the body. ADMA, which is 
the competitive inhibitor of NOS enzyme that allows the realization of NO synthesis, has an important place in the 
control of NO secretion. The increase in the amount of ADMA causes changes in the amount of NO. Especially 
in cases in which the amount of ADMA increases, some changes are observed in the cardiovascular system because 
NO level decreases (Tran et al. 2003; Böger and Ron 2005). Hermenegildo et al.(2002) investigated the plasma 
NO and ADMA levels in their study carried out on patients with thyroid dysfunction (Hemenegildo et al.2002). 
They reported that although NO levels were determined at a lower level in the hyperthyroidism group compared 
to the hypothyroidism group and the control group, ADMA level was found to be higher in the hyperthyroidism 
group compared to other two groups. In another study carried out by Arıkan et al. (2007) it was reported that NO 
level was at a significantly lower level in the hyperthyroidism group compared to the hypothyroidism and control 
groups, but ADMA level was at the higher level both in the hyperthyroidism and hypothyroidism groups compared 
to the control group (Arikan et a. l 2007). In our study, in line with the literature, serum NO level was higher in 
the hypothyroidism group compared to the serum NO level in the hyperthyroidism group, and the difference 
between them was statistically significant. In addition, serum ADMA levels in the hyperthyroidism group 
werefound to be statistically significantly higher than the ADMA levels of the other two groups. 
In this study, decreased NO and free oxygen radicals that increased in the case of hyperthyroidism can be the 
most important reasons for the increase in ADMA level in patients with hyperthyroidism. Furthermore, the 
relationship of thyroid diseases with the protein metabolism may affect the synthesis of ADMA which is the 
derivative of a methylarginine. ADMA and NO are very effective on the cardiovascular system (Albecht et al. 
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2003; Herman and Moncada 2005). The reduction of the amount of NO which is an important vasodilator is 
described as one of the earliest symptoms indicating the endothelial dysfunction. One of the most important factors 
that affect the amount of NO is the decrease in the amount of eNOS which is involved in NO synthesis (Tousoulis 
et al. 2012; Kampoli et al. 2012; Miyazaki et al.1999). ADMA is the competitive endogenous inhibitor of eNOS. 
The increase in ADMA level decreases the amount of NO and causes vasoconstriction in the arteries (Böger and 
Ron 2005; Vallance and Leiper 2004). 
Apelin is an important ring of this chain which is effective on the cardiovascular system. Serum apelin levels 
give important clues for the cardiovascular system. It has been reported by the studies carried out in recent years 
that apelin has significant effects on NO-dependent vasodilatation and on the cardiovascular system with some 
independent mechanisms (Kleinz and Davenport 2004; Mitra et al. 2006). 
In their study carried out in 2015, Gürel et al. (2015) examined the serum apelin levels in patients with thyroid 
dysfunction and found serum apelin levels higher than the control group (Gürel et al.2015) . Apelin receptors have 
been detected in the thyroid gland. Therefore, changes in the thyroid hormones and TSH may affect the release of 
adipocytokines, so there is a possible relationship between thyroid status, thyroid dysfunction and adipocytokines 
(Gueorguiev et al. 2001). 
  
5.Conclusions 
As the result, in our study, serum apelin levels were also found to be higher both in the hypothyroid and 
hyperthyroidism group compared to the control group. The fact that the average serum NO level was low but the 
amount of apelin was high in the hyperthyroidism group can be an important finding that should be investigated. 
The effects of apelin on many systems are still the subject of research and study, and there are differences in the 
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